Skip to content
aiqbench takeAI Products

aiqbench analysis

This article covers NetraMark's NetraAI, an explainable AI system that searches clinical trial data for patient subgroups that respond differently to a treatment. The pitch is plausible, but the piece gives no validation results, trial outcomes, or peer review, so the claims about reshaping trials remain unproven. Readers should watch for published evidence that subgroup findings hold up prospectively.
Source coveringQuantum Zeitgeist
What this isA model's reading of the article and related coverage, written for aiqbench. Not the publisher's words.

NetraAI finds hidden patterns in trial data to reshape drug trials

Quantum Zeitgeist2 min read

Joseph Geraci, PhD at NetraMark, applies concepts from theoretical physics—including advanced mathematics—to uncover hidden patterns in clinical trial data.

NetraMark is tackling a critical problem in drug development: clinical trials that appear to fail not because a drug is ineffective, but because positive responses are masked by patient variability.…

Excerpt shown under the publisher's RSS terms · 30 words · full text and figures are on the publisher's site

Related coverage